Rapamycin reverses ferroptosis by increasing autophagy in MPTP/MPP

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder where ferroptosis, a form of regulated cell death, is implicated in its pathology.
• Rapamycin, known for inducing autophagy, demonstrates neuroprotective potential in PD, but its specific interaction with ferroptosis remains unclear.

Purpose of the Study:

• To investigate the neuroprotective mechanism of rapamycin in Parkinson's disease, focusing on its role in regulating ferroptosis.
• To determine if rapamycin's effects are mediated through the modulation of ferroptosis and autophagy pathways.

Main Methods:

• Utilized a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of Parkinson's disease and a 1-methyl-4-phenylpyridinium (MPP+)-induced PC12 cell model.
• Administered rapamycin and assessed behavioral symptoms, dopamine neuron loss, and expression of ferroptosis markers (GPX4, SLC7A11, glutathione, MDA, ROS).
• Investigated the impact of a ferroptosis inducer and an autophagy inhibitor on rapamycin's neuroprotective effects.

Main Results:

• Rapamycin treatment significantly improved behavioral deficits and reduced dopaminergic neuron loss in PD model mice.
• Rapamycin administration decreased the expression of key ferroptosis indicators, including GPX4, SLC7A11, glutathione, MDA, and ROS, in both in vivo and in vitro models.
• The neuroprotective effects of rapamycin were diminished when co-administered with a ferroptosis inducer or an autophagy inhibitor, suggesting a link between these pathways.

Conclusions:

• Rapamycin exerts neuroprotective effects in Parkinson's disease models, potentially by inhibiting ferroptosis through autophagy activation.
• Targeting ferroptosis and modulating autophagy pathways represent promising therapeutic strategies for Parkinson's disease treatment.